Metabolism and pharmacokinetics of radium-223 in prostate cancer

Bibliography

• MRCooperberg, JMBroering, PWKantoff, PRCarroll. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007;178:S14-19
   PubMed Web of Science ®Google Scholar
• PHLange, RLVessella. Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev 1998;17:331-6
   PubMed Web of Science ®Google Scholar
• RERColeman. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s
   PubMed Web of Science ®Google Scholar
• CJRyan, EPElkin, JCowan, PRCarroll. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer 2007;110:81-6
   PubMed Web of Science ®Google Scholar
• IFTannock, Rde Wit, WRBerry, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• GDRoodman. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64
   PubMed Web of Science ®Google Scholar
• LBubendorf, ASchöpfer, UWagner, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83
   PubMed Web of Science ®Google Scholar
• APatrikidou, YLoriot, J-CEymard, et al. Who dies from prostate cancer? Prostate Cancer Prostatic Dis 2014;17:348-52
   PubMed Web of Science ®Google Scholar
• MLBrown. Bone scintigraphy in benign and malignant tumors. Radiol Clin North Am 1993;31:731-8
   PubMed Web of Science ®Google Scholar
• DPPetrylak, CMTangen, MHAHussain, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
   PubMed Web of Science ®Google Scholar
• Prostrate Cancer Fact Sheet. Surveillance, Epidemiology, and End Results Program (SEER). Available from: http://seer.cancer.gov [Last accessed 29 November 2014]
   Google Scholar
• MSBroder, BGutierrez, DCherepanov, YLinhares. Burden of skeletal-related events in prostate cancer: unmet need in pain improvement. Support Care Cancer 2015;23:237-47
   PubMed Web of Science ®Google Scholar
• YZheng, DBasel, S-OChow, et al. Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone. Clin Exp Metastasis 2014;31:921-33
   PubMed Web of Science ®Google Scholar
• TGuise. Examining the metastatic niche: targeting the microenvironment. Semin Oncol 2010;37(Suppl 2):S2-14
   PubMed Web of Science ®Google Scholar
• KMBussard, CVGay, AMMastro. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 2008;27:41-55
   PubMed Web of Science ®Google Scholar
• GAClines, KSMohammad, YBao, et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 2007;21:486-98
   PubMed Web of Science ®Google Scholar
• GAClines, TAGuise. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 2008;10:e7
   PubMedGoogle Scholar
• PWKantoff, SHalabi, MConaway, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506-13
   PubMed Web of Science ®Google Scholar
• IFTannock, DOsoba, MRStockler, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64
   PubMed Web of Science ®Google Scholar
• MJMoore, DOsoba, KMurphy, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994;12:689-94
   PubMed Web of Science ®Google Scholar
• RGRobinson. Strontium-89–precursor targeted therapy for pain relief of blastic metastatic disease. Cancer 1993;72:3433-5
   PubMed Web of Science ®Google Scholar
• RGRobinson, DFPreston, KGBaxter, et al. Clinical experience with strontium-89 in prostatic and breast cancer patients. Semin Oncol 1993;20:44-8
   PubMed Web of Science ®Google Scholar
• MARitter, JECleaver, CATobias. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature 1977;266:653-5
   PubMed Web of Science ®Google Scholar
• CUrch. The pathophysiology of cancer-induced bone pain: current understanding. Palliat Med 2004;18:267-24
   PubMed Web of Science ®Google Scholar
• RGRobinson, GMBlake, DFPreston, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989;9:271-81
   PubMedGoogle Scholar
• GMBlake, MAZivanovic, AJMcEwan, DMAckery. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986;12:447-54
   PubMedGoogle Scholar
• GONOosterhof, JTRoberts, TMde Reijke, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a Phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003;44:519-26
   PubMed Web of Science ®Google Scholar
• PMQuilty, DKirk, JJBolger, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33-40
   PubMed Web of Science ®Google Scholar
• RSciuto, AFesta, SRea, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002;43:79-86
   PubMed Web of Science ®Google Scholar
• AHLaing, DMAckery, RJBayly, et al. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 1991;64:816-22
   PubMed Web of Science ®Google Scholar
• IGFinlay, MDMason, MShelley. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005;6:392-400
   PubMed Web of Science ®Google Scholar
• RGRobinson, DFPreston, MSchiefelbein, KGBaxter. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995;274:420-4
   PubMed Web of Science ®Google Scholar
• ATPorter, AJMcEwan, JEPowe, et al. Results of a randomized Phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13
   PubMed Web of Science ®Google Scholar
• SSmeland, BErikstein, MAas, et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 2003;56:1397-404
   PubMed Web of Science ®Google Scholar
• CCollins, JFEary, GDonaldson, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a Phase I/II trial. J Nucl Med 1993;34:1839-44
   PubMed Web of Science ®Google Scholar
• TFSandeman, RSBudd, JJMartin. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate. Clin Oncol (R Coll Radiol) 1992;4:160-4
   PubMedGoogle Scholar
• ANSerafini, SJHouston, IResche, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998;16:1574-81
   PubMed Web of Science ®Google Scholar
• OSartor, RHReid, PJHoskin, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940-5
   PubMed Web of Science ®Google Scholar
• MJMorris, NPandit-Taskar, JCarrasquillo, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 2009;27:2436-42
   PubMed Web of Science ®Google Scholar
• KFizazi, PBeuzeboc, JLumbroso, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009;27:2429-35
   PubMed Web of Science ®Google Scholar
• MLassmann, DNosske. Dosimetry of 223Ra-chloride: dose to normal organs and tissues. Eur J Nucl Med Mol Imaging 2013;40:207-12
   PubMed Web of Science ®Google Scholar
• GHenriksen, KBreistøl, OSBruland, et al. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62:3120-5
   PubMed Web of Science ®Google Scholar
• SNilsson, RHLarsen, SDFosså, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 2005;11:4451-9
   PubMed Web of Science ®Google Scholar
• SNilsson, LFranzén, CParker, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled Phase II study. Lancet Oncol 2007;8:587-94
   PubMed Web of Science ®Google Scholar
• CParker, SNilsson, DHeinrich, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23
   PubMed Web of Science ®Google Scholar
• PHoskin, OSartor, JMO’Sullivan, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, Phase III ALSYMPCA trial. Lancet Oncol 2014;15:1397-406
   PubMed Web of Science ®Google Scholar
• EBasch, DALoblaw, TKOliver, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: american Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014;32:3436-48
   PubMed Web of Science ®Google Scholar
• MSCookson, WTLowrance, MHMurad, ASKibel. Castration-Resistant Prostate Cancer: AUA Guideline Amendment. J Urol 2015;193(2):491-9
   PubMed Web of Science ®Google Scholar
• GAClines, TAGuise. Molecular mechanisms and treatment of bone metastasis. Semin Oncol 2010;37:S2-S14
   Google Scholar